ARS Pharmaceuticals, Inc. (SPRY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.62-0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
ARS Pharmaceuticals is growing revenue from $7.97M in 2025-Q1 to $22.68M in 2026-Q1. Full-year 2025 revenue reached $84.3 million. Improved access to its product Neffy supports growth. New CEO may drive better execution.
The company is still loss-making with negative EPS expected through 2027. Recent earnings misses and a guidance cut show financial challenges. Competition and litigation risks may hurt growth.
The stock trades about 32% below our fair value near $12. Analysts expect about 89% revenue growth, which is optimistic given recent earnings misses and guidance cuts.
Breaks if: retail access program fails to expand or is withdrawn
Breaks if: no improvement in execution or further operational setbacks
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The company is currently loss-making, with recent financial performance being weak, but it has potential for recovery through targeted revenue growth and cost optimization efforts.
The market appears to have priced in a low expectations gap, indicating that investors are cautious about SPRY's future performance. The valuation is considered cheap compared to peers, reflecting the challenges the company faces.
Management is focused on driving revenue growth and implementing cost discipline, though recent results show mixed progress. The company has a high probability of missing earnings expectations, which adds to the uncertainty in the near term.
The thesis hinges on management's ability to execute on their priorities, particularly in revenue growth and cost management. Additionally, broader sector performance and economic indicators, such as job reports, will play a crucial role in shaping SPRY's future.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company reported a Q2 EPS of 63 cents, beating the consensus of 49 cents. This indicates strong commercial execution and supports revenue growth. However, the latest earnings miss challenges the company's ability to drive revenue growth effectively.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $84 million in FY26
In the next 1 to 3 years, SPRY's performance will depend on effective management execution and external economic factors. Not investment advice.